Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

Inclusion Criteria

• •Patients ≥ 18 years of age
• •recurrent ovarian, peritoneal, or tubal cancer and prior treatment with platinum- and paclitaxel were eligible to this trial.
• •Eastern Cooperative Oncology Group (ECOG) performance status less than 3.
• •renal function (serum creatinine 1.25 times the upper limit of normal, glomerular filtration rate greater than 60 ml/min)
• •liver function (AST/ ALT three times the upper limit of normal, bilirubin concentrations 1.25 the upper limit of normal)
• •bone marrow function (neutrophil count greater than 1.5 x 109/l, and a platelet count greater than 100 x 109/l).